CR8426A - ANTI-IGF-I RECEIVER ANTIBODY - Google Patents

ANTI-IGF-I RECEIVER ANTIBODY

Info

Publication number
CR8426A
CR8426A CR8426A CR8426A CR8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A
Authority
CR
Costa Rica
Prior art keywords
antibodies
igf
cancer
receptor
elevated levels
Prior art date
Application number
CR8426A
Other languages
Spanish (es)
Inventor
Singh Rajeeva
J Tavares Daniel
E Dagdigian Nancy
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of CR8426A publication Critical patent/CR8426A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Los anticuerpos, anticuerpos humanizados, anticuerpos recubiertos, fragmentos de anticuerpo, anticuerpos derivatizados y conjugados de los mismos con agentes citotoxicos, que especificamente se enlazan a, e inhiben al receptor del factor I de crecimiento de tipo insulina, antagonizan los efectos de IGF-l, IGF-lI y suero en el crecimiento y supervivencia de celulas de tumor, y que substancialmente carecen de actividad agonista. Los anticuerpos y fragmentos de los mismos por consiguiente se pueden utilizar, opcionalmente en conjuncion con otros agente terapeuticos, en el tratamiento de tumores que expresan niveles elevados del receptor IGF-l, tales como cancer de pecho, cancer de colon, cancer de pulmon, sarcoma sinovial, cancer de prostata, y cancer pancreatico, y los anticuerpos derivatizados se pueden utilizar en el diagnostico y formacion de imagenes de tumores que expresan niveles elevados del IGF-I.Antibodies, humanized antibodies, coated antibodies, antibody fragments, derivatized antibodies and conjugated thereof with cytotoxic agents, which specifically bind to, and inhibit the insulin-like growth factor I receptor, antagonize the effects of IGF-1. , IGF-lI and serum in the growth and survival of tumor cells, and which substantially lack agonist activity. The antibodies and fragments thereof can therefore be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors expressing elevated levels of the IGF-1 receptor, such as breast cancer, colon cancer, lung cancer, Synovial sarcoma, prostate cancer, and pancreatic cancer, and derivatized antibodies can be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I.

CR8426A 2003-12-08 2006-06-01 ANTI-IGF-I RECEIVER ANTIBODY CR8426A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody

Publications (1)

Publication Number Publication Date
CR8426A true CR8426A (en) 2007-12-04

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8426A CR8426A (en) 2003-12-08 2006-06-01 ANTI-IGF-I RECEIVER ANTIBODY

Country Status (13)

Country Link
EP (1) EP1692176A4 (en)
JP (1) JP2008502589A (en)
KR (1) KR20070001883A (en)
CN (1) CN1886424A (en)
AU (1) AU2004303792A1 (en)
BR (1) BRPI0417406A (en)
CA (1) CA2548065A1 (en)
CR (1) CR8426A (en)
EA (1) EA009807B1 (en)
EC (1) ECSP066595A (en)
IL (1) IL174770A0 (en)
MX (1) MXPA06005540A (en)
NO (1) NO20063155L (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
KR20130065665A (en) * 2010-05-11 2013-06-19 아베오 파마슈티컬즈, 인크. Anti-fgfr2 antibodies
EP2766478A4 (en) 2011-10-10 2015-06-17 Los Angeles Childrens Hospital NOVEL ASPARAGINASE AND METHODS FOR TREATING DISEASES ASSOCIATED WITH ASPARAGIN DEPENDENCE
CN103509117B (en) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 Bi-specific antibody of anti-human HER2 and people IGF-IR and its production and use
CN110691794B (en) * 2017-05-30 2023-10-27 帝人制药株式会社 anti-IGF-I receptor antibodies
CN118615438A (en) * 2023-03-07 2024-09-10 康方药业有限公司 Drug combination comprising anti-CTLA4-anti-PD-1 bispecific antibody and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351452A1 (en) * 1998-12-04 2000-06-15 Novartis Ag Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3
EP2796468A2 (en) * 2001-01-05 2014-10-29 Pfizer Inc Antibodies to insulin-like growth factor I receptor
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
CA2514231A1 (en) * 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies

Also Published As

Publication number Publication date
IL174770A0 (en) 2006-08-20
EP1692176A4 (en) 2008-11-12
EP1692176A1 (en) 2006-08-23
JP2008502589A (en) 2008-01-31
CA2548065A1 (en) 2005-07-07
MXPA06005540A (en) 2006-08-17
EA200600931A1 (en) 2006-10-27
AU2004303792A1 (en) 2005-07-07
EA009807B1 (en) 2008-04-28
BRPI0417406A (en) 2007-04-03
NO20063155L (en) 2006-08-11
KR20070001883A (en) 2007-01-04
CN1886424A (en) 2006-12-27
ECSP066595A (en) 2006-10-17

Similar Documents

Publication Publication Date Title
AR061911A1 (en) ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER
ATE507244T1 (en) ANTI-IGF-I RECEPTOR ANTIBODIES
PE20080663A1 (en) TUMOR THERAPY WITH A COMBINATION OF ANTI-HER2 ANTIBODIES
SG158119A1 (en) Anti-integrin immunoconjugates, methods and uses
AR070862A1 (en) COMBINATION THERAPY WITH C-MET AND HER ANTAGONISTS
CL2017001580A1 (en) Antibody or antibody fragment against humanized antibody cd38, conjugated to the antibody with a cytotoxic compound pharmaceutical composition with said antibodies using antibodies to treat cancer or autoimmune disease method to diagnose cancer polynucleotide vector and host cell.
AR061245A1 (en) COMPOSITIONS AND METHODS FOR VASCULAR DEVELOPMENT MODULATION
PT2326665E (en) Non-cytotoxic fusion proteins comprising egf muteins
WO2006099141A3 (en) Anti-mesothelin antibodies
AR054175A1 (en) NEW ANTI-IGF-IR ANTIBODIES AND USES OF THE SAME
AR054254A1 (en) ADJUTIVE THERAPY WITH TRASTUZUMAB (REGISTERED HERCEPTIN)
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
DOP2013000045A (en) ANTI-OX40 ANTIBODIES AND METHODS OF THE SAME USE
NZ599707A (en) Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
WO2007100640A3 (en) Growth hormone receptor antagonist cancer treatment
CR8426A (en) ANTI-IGF-I RECEIVER ANTIBODY
WO2011137245A3 (en) Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
CO6331345A2 (en) COMPOSITIONS AND METHODS THAT PROVIDE A CELLED HYBRIDOMINE LINE DEPOSITED AS NO. OF ACCESS ATCC PTA-9387 AND AN ANTIBODY PRODUCED BY THIS HYBRIDOMA CELL LINE
EP1909783A4 (en) LIQUID ANALOGUES USEFUL AS ANTICANCER AGENTS
Heller et al. Neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy followed by docetaxel in refractory patients with locally advanced breast cancer
EA200601405A1 (en) HUMANIZED ANTIBODY
Shi et al. Antibody-drug conjugates in breast cancer: advances and prospects
JP2018516230A5 (en)
MD2849G2 (en) Method of mammary cancer treatment to patients of old age
Abbasova et al. Neuroendocrine carcinoma of the prostate (review of the literature)

Legal Events

Date Code Title Description
FC Refusal